Physician
Oncology
Kyle Holen practices Oncology. He went to Columbia University College of Physicians & Surgeons. Columbia University College of Physicians & Surgeons is one of the top medical schools in the US. Columbia University College of Physicians & Surgeons is ranked 8 in research and 52 in primary care medicine Dr. Kyle D. Holen is a published doctor and has 46 publications published. The lastest was: 'Safety, efficacy, and pharmacokinetics of navitoclax (ABT-263) in combination with irinotecan: results of an open-label, phase 1 study.' He is registered with Medicare and accepts Medicare payments.
Publications
- Safety, efficacy, and pharmacokinetics of navitoclax (ABT-263) in combination with erlotinib in patients with advanced solid Tumors.
- Safety, efficacy, and pharmacokinetics of navitoclax (ABT-263) in combination with irinotecan: results of an open-label, phase 1 study.
- A multicenter phase 1 study of γ -secretase inhibitor RO4929097 in combination with capecitabine in refractory solid Tumors.
- A phase I study of vorinostat in combination with bortezomib in patients with advanced Malignancies.
- Vorinostat in combination with bortezomib in patients with advanced Malignancies directly alters transcription of target genes.
- A phase I study of sorafenib, oxaliplatin and 2 days of high dose capecitabine in advanced pancreatic and biliary tract Cancer: a Wisconsin oncology network study.
- First-time-in-human study of GSK923295, a novel antimitotic inhibitor of centromere-associated protein E (CENP-E), in patients with refractory Cancer.
- Phase 2 study of bevacizumab plus erlotinib in patients with advanced hepatocellular Cancer.
- Activity of Oxaliplatin Plus Capecitabine (CapeOx) With Lapatinib for Metastatic ColoRectal Cancer: Results From Two Patients Treated on a Clinical Study.
- A Pilot Phase II Study of Valproic Acid for Treatment of Low-Grade Neuroendocrine Carcinoma.
- A phase I study of capecitabine, oxaliplatin, and lapatinib in metastatic or advanced solid Tumors.
- Cytotoxic Evaluation of 3-Aminopyridine-2-Carboxaldehyde Thiosemicarbazone, 3-AP, in Peripheral Blood Lymphocytes of Patients with Refractory Solid Tumors using Electr...
- A preclinical and clinical study of lithium in low-grade neuroendocrine Tumors.
- Report of a multicenter phase II trial testing a combination of biweekly bevacizumab and daily erlotinib in patients with unresectable biliary Cancer: a phase II Conso...
- A phase II study of oxaliplatin, 5-fluorouracil, leucovorin, and high-dose capecitabine in patients with metastatic coloRectal cancer.
- A multicenter, phase II study of Bortezomib (PS-341) in patients with unresectable or metastatic gastric and gastroEsophageal junction adenocarcinoma.
- More on reports of esophageal Cancer with oral bisphosphonate use.
- Phase I trial of 2-methoxyestradiol NanoCrystal dispersion in advanced solid Malignancies.
- Beyond taxanes: a review of novel agents that target mitotic tubulin and microtubules, kinases, and kinesins.
- A phase 2 consortium (P2C) trial of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP) for advanced adenocarcinoma of the pancreas.
- A phase I trial of CEP-701 + gemcitabine in patients with advanced adenocarcinoma of the pancreas.
- Electron paramagnetic resonance study of peripheral blood mononuclear cells from patients with refractory solid Tumors treated with Triapine.
- Guillain-Barré syndrome after treatment with sunitinib malate?
- Biologic study of the effects of octreotide-LAR on growth hormone in unresectable and metastatic hepatocellular carcinoma.
- Target practice: figuring out which, when, and why to use systemic therapies for metastatic colon Cancer.
- A dramatic response to long-acting octreotide in metastatic hepatocellular carcinoma.
- Clinical characteristics and outcomes from an institutional series of acinar cell carcinoma of the pancreas and related Tumors.
- Evaluation of mRNA by Q-RTPCR and protein expression by AQUA of the M2 subunit of ribonucleotide reductase (RRM2) in human Tumors.
- Therapeutic and palliative options for diffuse Neuroendocrine metastatic disease.
- An international, multicenter phase II trial of bortezomib in patients with hepatocellular carcinoma.
- ZM336372, a Raf-1 activator, suppresses growth and Neuroendocrine hormone levels in carcinoid tumor cells.
- ZM336372 induces apoptosis associated with phosphorylation of GSK-3beta in Pancreatic adenocarcinoma cell lines.
- A phase I trial of gemcitabine in combination with patupilone in patients with advanced solid Tumors.
- Metastatic neuroendocrine hepatic Tumors: resection improves survival.
- The pharmacokinetics, toxicities, and biologic effects of FK866, a nicotinamide adenine dinucleotide biosynthesis inhibitor.
- ZM336372, a Raf-1 activator, causes suppression of proliferation in a human hepatocellular carcinoma cell line.
- Population pharmacokinetics of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (Triapine®) in Cancer patients.
- Volociximab, a chimeric monoclonal antibody that specifically binds alpha5beta1 integrin: a phase I, pharmacokinetic, and biological correlative study.
- Treatment with panitumumab after a severe infusion reaction to cetuximab in a patient with metastatic coloRectal cancer: a case report.
- A first in human study of SB-743921, a kinesin spindle protein inhibitor, to determine pharmacokinetics, biologic effects and establish a recommended phase II dose.
- A phase I study of an oral simulated FOLFOX with high dose capecitabine.
- New therapies, new directions: advances in the systemic treatment of metastatic coloRectal cancer.
- Dose-escalation study of fixed-dose rate gemcitabine combined with capecitabine in advanced solid Malignancies.
- The maximum tolerated dose and biologic effects of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP) in combination with irinotecan for patients with refractor...
- Amongst eligible patients, age and comorbidity do not predict for dose-limiting toxicity from phase I chemotherapy.
Schools
Columbia University College of Physicians And Surgeons
Ny and Presby Hospital
Conditions Treated
- Anal and Rectal Cancer
- Anemia
- Bladder Cancer
- Breast Cancer
- View All
Doctors Specialties
- Medical Oncology
- Oncology
Accepted Insurances
- American Republic
- Great West Healthcare-Cigna PPO
- Health Alliance PPO
- Choice Care PPO
- Preferred PPO
- Medicare MCR
Education
-
Memorial Sloan-Kettering Cancer Center
-
New York Presbyterian Hospital
-
Columbia University College of Physicians & Surgeons
Hospital
-
University of Wisconsin Hospital and Clinics
Drug Facts
| NPI NUMBER |
|
1316908783 |
| NPPES Provider LastName |
|
HOLEN |
| NPPES Provider FirstName |
|
KYLE |
| NPPES Provider ZIPCode |
|
537920001 |
| NPPES Provider State |
|
WI |
| Specialty Description |
|
Hematology/Oncology |
| Total Claim Count |
|
68.0 |
| Distinct Opioid Count |
|
0.0 |
| Opioid Claim Count |
|
0.0 |
| Percent Opioid Claims |
|
0.0 |
Helpful Reviews
Give
Anonymous Review
Medicare Facts
| National Provider Identifier [NPI] |
1316908783 |
| Last Name Of The Provider |
HOLEN |
| First Name Of The Provider |
KYLE |
| View All |
|
Similar Doctors
Doctor Directory | TOS | twitter | FB | Angel | blog
This Doctor is OpenDoctor Recommended.